Search Results
Hodgkin Lymphoma: Upfront Brentuximab Vedotin + AVD
Debate: Best upfront approach for Advanced Stage Hodgkin Lymphoma? - A (brentuximab vedotin) VD
The Rationale for Exploring Brentuximab Vedotin Plus AVD in Hodgkin Lymphoma
Debate: Brentuximab vedotin as upfront therapy for advanced Hodgkin lymphoma? - Yes
Phase 2 trial of brentuximab vedotin plus AVD for non-bulky limited-stage Hodgkin lymphoma
Phase 2 trial of brentuximab vedotin plus AVD for limited-stage Hodgkin lymphoma
FDA Approval of Brentuximab Vedotin Plus AVD in Classical Hodgkin Lymphoma
Brentuximab Vedotin Plus AVD: Limiting Toxicity in Limited-Stage Hodgkin Lymphoma
Brentuximab Vedotin in Hodgkin Lymphoma
ECHELON-1 AYA subgroup results: brentuximab vedotin plus AVD vs. ABVD
5-year follow-up of ECHELON-1: brentuximab plus AVD versus ABVD in Hodgkin lymphoma
Hodgkin Lymphoma: Using Brentuximab Vedotin Frontline
